Six weeks before the hoopla over President Barack Obama's executive order lifting restrictions on embryonic-stem-cell research, Hans Keirstead, a scientist at the University of California, Irvine, was already sipping champagne. In 2005 Keirstead had published a study showing that a therapy derived from human embryonic stem cells could make partially paralyzed rats walk. Now he'd gotten word that the FDA had cleared the way for Geron, a small biotech company in California, to launch the first clinical trial of the treatment in human beings with spinal-cord injuries. It was incredible news,not just for Keirstead, who'd been wanting to invent a therapy for brain and spinal-cord disorders since he was 11 years old, but for scientists who believe human embryonic stem cells can teach them about complex diseases and potentially lead to cures. Keirstead, 41, and his team of scientists hailed the news over a case of chilled Veuve Clicquot. "We put the last bottle down about six hours later," Keirstead says. "It was just a really fun time."
Opinions about the moral status of an embryo won't change with presidential decrees or FDA decisions, so you can bet that the debate over embryonic-stem-cell research is far from over. But no matter how loud the chatter gets, the science is about to leave the Petri dish. For years, academic researchers have felt stymied by limitations imposed by George W. Bush that allowed federal funding only for research on 21 embryonic-stem-cell lines that already existed. Scientists who wanted to pursue newer cells had to find private dollars, some of which came from state initiatives. Geron, meanwhile, had its own money and was doggedly pursuing its mission to get human embryonic-stem-cell treatments into people. This summer, the company plans to enroll the first of up to 10 patients in a clinical trial that everyoneclinicians, scientists, biotechs, patients, ethicistswill be watching. There is plenty of excitement from people with spinal-cord injuries and their physicians, who can offer little hope for any significant improvement right now. But some scientists are concerned that the research may not be ready for prime time. The simple truth: even if all goes perfectly in the early stage of the trial, which tests for safety, no one with a spinal-cord injury is going to be cured any time soon. Peter Kiernan, chairman of the Christopher and Dana Reeve Foundation, says he is constantly balancing hope against hype among patients. "I feel like I'm in a car turning the steering wheel at the same time that I'm pushing on the brakes."
From the start, Geron's MO has been to put foot to accelator. It is, after all, a company ($200 million in the bank) whose primary goalfor patients and, of course, stockholdersis to get a treatment to market. In 2001 it funded Keirstead's research, which tested a therapy manufactured from human embryonic stem cells (from a Bush-approved cell line), called oligodendrocyte progenitor cells, in rats with a partial spinal-cord injury. When the cells were injected into the damaged area, they restored the spinal cord's insulation, which conducts nerve impulses from the brain to the rest of the body, allowing movement. In Keirstead's study, rats who had 10-month-old injuries didn't improve because too much scarring had developed. But the outcome was striking in animals whose injuries were just seven days old. Two months after treatment, rats who'd lost control of their trunk muscles, tail and hind legsthey could move, but not muchnow exhibited "substantially improved locomotor ability." They could walk.
Nice if you're a rat. Now the company had to figure out how to move the cells into humans. It spent years creating the optimal oligodendrocyte progenitor cell, then focused on how to make a bunch of them identically under strict quality controla process that's a whole lot harder with a living cell than a pill. It even designed a computer-controlled device to position the syringe and control the injection to be sure that the right number of cells went to the right spot. By the time Geron filed its application to the FDA last year, it had 22,500 pages of documentation. Total count: 24 studies, 1,977 rodents, $45 million.
Now Geron is negotiating with up to eight neurotrauma centers to conduct human trials. It will be recruiting people who have injuries in the thoracic, or middle region of the spineparaplegics who are paralyzed from the chest area down. Because the injuries must be newless than 14 days oldthe patients Geron wants to start enrolling this summer are actually healthy people today who haven't yet been injured. But that hasn't stopped the interest among people who are already paralyzed. When the FDA approval was announced in January, Geron's voice-mail system broke down from the flood of calls.
It's not hard to see how important this trial is. Everybody you talk to in the spinal-cord community worries about patients traveling overseas for risky, ambiguous cellular therapies, forking out tens of thousands of dollars and praying for a miracle. Kate Willette, whose husband was paralyzed in a skiing accident eight years ago, understands the desire to get better. Earlier this month she attended a gathering of researchers and the spinal-cord community where she watched Keirstead, dressed in jeans and an untucked white shirt, tell the crowd, "I can't promise you anything, but we're doing our damnedest." Willette, who moderates an online forum for families of people with spinal-cord injuries, says Keirstead is cautious, but exudes a welcome sense of confidence. "I can't tell you how exciting it is," she says of the Geron trial. "Either it's going to work or it's not, but we'll have something to hang our hats on." Of Keirstead, she says: "He's a rock star."
Keirstead's animal research was published in a peer-reviewed journal, but much of Geron's other preclinical documentation has been under wraps; only the company and the FDA know what it says. That leaves some researchers feeling unsettled. What's the precise mechanism of action? Could the cells prompt an immune response in patients? Or generate certain fibers that cause pain? Should Geron perform experiments in other types of animals before they go to humans? John Gearhart, a pioneering researcher whose early stem-cell work was funded by Geron and who is now director of the Institute for Regenerative Medicine at the University of Pennsylvania, says he wants the trial to succeed, but he constantly worries about safety. Gearhart wonders if there might not be some number of cells in Geron's therapy that don't behave as scientists want them tothey don't differentiate themselves into the desired cell type after they're injected. Research has shown that such cells may form tumors or interfere with normal function, and it is difficult to say for sure how many months or years later that might occur. For Larry Goldstein, director of the University of California, San Diego, stem-cell program, a key issue is risk versus benefit. While paraplegia is by no means easy to endure, people do adapt and can have fulfilling lives. What if the treatment causes harm? Ideally, Goldstein would have liked the first human embryonic-stem-cell therapy tested in a disease that leads inexorably to death, like ALS. "I'm nervous," he says. This first trial is "a high-wire act."
Geron's CEO, Dr. Thomas Okarma, says he understands the anxiety. "Nobody wants another Jesse Gelsinger here," he says, referring to the teen who died in a 1999 trial for gene therapy, another pioneering technique. The company, he says, has "lifted stones as far and high as we can to assure ourselves the safety of this product." The
oligodendrocyte cells it is injecting (each patient will receive a syringe of 2 million cells) are "highly characterized," meaning it's seen no evidence of any outliers that might cause trouble down the road. Its tests found no tumors in rodents over the course of a year and no evidence of an immune response (patients will be given immunosuppressants for 45 to 60 days after treatment, but that's to be sure there's no inflammation in the injury site, which might destroy the injected cells).
Patients will be closely monitored with MRIs for the first year and followed for a total of 15 years. And trial volunteers will have complete injuries "with no hope of recovery," making the risk worth the potential payoff, says Okarma. Geron's mantra is "living cells will be tomorrow's pills," he says. And he is confident it will get there. So confident, he believes the oligodendrocyte progenitor cells might be applicable to other nervous-system disorders, like multiple sclerosis, Alzheimer's and stroke. Geron plans to publish more of its preclinical data, Okarma says, but in the meantime, the public should be assured that the company has done rigorous research. "Companies die when they're not successful, when a product is harmful or it doesn't work," he says. "The last thing we want to do is be wrong. The future of the company depends on this." Keirstead, for his part, says the first thing he asks when people say "slow down" is "Do you know anyone in a wheelchair?'"
Everybody wants to be cautious, but researchers, clinicians, patients and biotechs differ on how much risk they can live with and when to pull the trigger. Gearhart says his conservative approach butts up against others in the field. "Every time I say 'be circumspect,' my clinical friends are hitting me upside the head, saying, 'You've got to do it at some point'." That is the view of Dr. Gary Steinberg, a professor of neurosurgery at Stanford, a potential site for Geron's trial. "I'm highly enthusiastic," he says. Steinberg says he has faith in the FDA's review. Without effective treatments currently available, patients with spinal-cord injuries are left with little recourse. "There's a significant unmet need," he says. At the Miami Project to Cure Paralysis, scientific director W. Dalton Dietrich says he has concernsthis is a first, after allbut he also believes researchers will learn a great deal about how to use cellular therapies in humans, something that will help educate and advance the field.
More here:
The First Embryonic Stem Cell Trial
- Stem Cells In Human Trials - September 15th, 2011 [September 15th, 2011]
- NZ Stemcell Trials - Part One - September 15th, 2011 [September 15th, 2011]
- CIRM Major Facilities Speed Stem Cell Science and Create Jobs - September 15th, 2011 [September 15th, 2011]
- Geron's Embryonic Stem Cell Clinical Trial for Spinal Cord Injury - September 15th, 2011 [September 15th, 2011]
- Hans Keirstead - Stem Cell Research Human Clinical Trials - September 15th, 2011 [September 15th, 2011]
- Stem-Cell Human Trials - September 15th, 2011 [September 15th, 2011]
- Geron: FDA Clearance for Human Clinical Stem Cell Trials - September 15th, 2011 [September 15th, 2011]
- Eric Legrand Rutgers University shout out, Listen up! - September 20th, 2011 [September 20th, 2011]
- How to Mend a Broken Heart - September 20th, 2011 [September 20th, 2011]
- Human Embryonic Stem Cell History! - September 20th, 2011 [September 20th, 2011]
- Robert Lanza - ACT - Stem cells and organ cloning interview - September 20th, 2011 [September 20th, 2011]
- Toonari Post Health News: Europe's first clinical trial using human embryonic stem cells - September 23rd, 2011 [September 23rd, 2011]
- Diabetes: Spotlight on Stem Cell Research - Ed Baetge - September 23rd, 2011 [September 23rd, 2011]
- Talking Apes being created by Science | Planet of the Apes, here we come! - September 24th, 2011 [September 24th, 2011]
- Health news: Internet use, sleep, human stem cell research - September 24th, 2011 [September 24th, 2011]
- Geron - September 24th, 2011 [September 24th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - A Father's Story - September 24th, 2011 [September 24th, 2011]
- The Frankenstein Syndrome Trailer - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Patient Stories - September 24th, 2011 [September 24th, 2011]
- Geron Corp. Initiates First Human Study Of Embryonic Stem-Cell Therapy - September 24th, 2011 [September 24th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - September 24th, 2011 [September 24th, 2011]
- Stemcells come alive: Fix Mouse with severed spine ABCnews - September 24th, 2011 [September 24th, 2011]
- StemCells Gains 5% on Neural Stem Cell Trial in Spinal Cord Injury - September 24th, 2011 [September 24th, 2011]
- Stem-Cell Research on Animals - September 24th, 2011 [September 24th, 2011]
- First hESC Therapy Clinical Trial - September 24th, 2011 [September 24th, 2011]
- Stem Cell Testing on Human Subjects [Officially] Begins • NBC Nightly News • October 11th, 2010 - September 24th, 2011 [September 24th, 2011]
- Leukemia: Spotlight on Stem Cell Research - Catriona Jamieson - September 24th, 2011 [September 24th, 2011]
- First stem cell trial begins - September 24th, 2011 [September 24th, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Arnold Kriegstein - September 24th, 2011 [September 24th, 2011]
- Becoming a Blood Stem Cell Donor - September 24th, 2011 [September 24th, 2011]
- Stem cells might be able to reverse the effects of a heart attack. - September 24th, 2011 [September 24th, 2011]
- Horse Stem Cell Video.mp4 - September 25th, 2011 [September 25th, 2011]
- Stem cell trials to begin - September 25th, 2011 [September 25th, 2011]
- Lou Gehrig's Disease (ALS): Progress and Promise in Stem Cell Research - September 25th, 2011 [September 25th, 2011]
- Hans Keirstead - September 25th, 2011 [September 25th, 2011]
- Stem Cell Quiz - September 25th, 2011 [September 25th, 2011]
- NZ Stemcell Trials - Part Two - September 25th, 2011 [September 25th, 2011]
- Drug Trials in a Dish - September 25th, 2011 [September 25th, 2011]
- Rise and Walk - September 25th, 2011 [September 25th, 2011]
- Catriona Jamieson: Therapies Based on Cancer Stem Cells - September 27th, 2011 [September 27th, 2011]
- Vatican lending hand in adult stem cell research - September 28th, 2011 [September 28th, 2011]
- Why STEM-Enhance? - September 28th, 2011 [September 28th, 2011]
- Genetic Underpinnings of Alopecia Areata - September 29th, 2011 [September 29th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Ann Tsukamoto - September 29th, 2011 [September 29th, 2011]
- stem cell trial for leading causes of blindness - October 9th, 2011 [October 9th, 2011]
- Forbes Discusses Stem Cell Research - Video - October 13th, 2011 [October 13th, 2011]
- Bruce Conklin: Drug screening with stem cells - Video - October 13th, 2011 [October 13th, 2011]
- Human Trials of Embryonic Stem Cell Treatment Beginning - Video - October 13th, 2011 [October 13th, 2011]
- Rise and Walk - Video - October 13th, 2011 [October 13th, 2011]
- Mesenchymal Stem Cell Trials - Video - October 14th, 2011 [October 14th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video - October 14th, 2011 [October 14th, 2011]
- Better Drugs Through Stem Cells - Video - October 16th, 2011 [October 16th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue / Video - Video - October 16th, 2011 [October 16th, 2011]
- GARY RABIN- ADVANCED CELL TECHNOLOGIES 2011 - Video - October 21st, 2011 [October 21st, 2011]
- Stem cell treatment on horse a success, vet says - Video - October 21st, 2011 [October 21st, 2011]
- MAJOR EMBRYONIC STEM CELL BREAKTHROUGHS - Video - October 22nd, 2011 [October 22nd, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video - November 13th, 2011 [November 13th, 2011]
- Human Cloning has Begun | Playing God? - Video - November 15th, 2011 [November 15th, 2011]
- Diabetes: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video - November 15th, 2011 [November 15th, 2011]
- Double Blind Trial of Stem Cells for Heart Failure - Video - December 4th, 2011 [December 4th, 2011]
- Cardiac Stem Cell Therapy Clinical Trial - Video - December 4th, 2011 [December 4th, 2011]
- Glasgow Hospital Conducts First Stem Cell Trials on Stroke Patients - Video - December 4th, 2011 [December 4th, 2011]
- Dr Dietrich discusses the Geron stem cell trial to treat acute spinal cord injury - Video - December 4th, 2011 [December 4th, 2011]
- Stem Cell Research Today: Larry Goldstein - CIRM Science Writer's Seminar - Video - December 7th, 2011 [December 7th, 2011]
- Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video - December 22nd, 2011 [December 22nd, 2011]
- Clinical trials and stem cells: what patients should consider - Video - January 2nd, 2012 [January 2nd, 2012]
- Spare Parts for Humans: Tissue Engineers Aim for Lab-Grown Limbs, Lungs and More - Video - January 4th, 2012 [January 4th, 2012]
- CIRM Grant Writing: RFA's - Where does your Project Fit? - Video - January 5th, 2012 [January 5th, 2012]
- Prometheus and I: building new body parts from stem cells (15 Nov 2011) - Video - January 5th, 2012 [January 5th, 2012]
- News Bulletin 18 November 2011 -- The Christian Institute - Video - January 5th, 2012 [January 5th, 2012]
- The Brain on Trial: How Neuroscience Challenges the Law as We Know It - Video - January 5th, 2012 [January 5th, 2012]
- The Human Genome and Individualized Medicine - David Valle, MD - Video - January 5th, 2012 [January 5th, 2012]
- 2010 Professional of Distinction - Discovery Awards - Video - January 23rd, 2012 [January 23rd, 2012]
- Research at The Nebraska Medical Center Biologics Production Facility - Video - January 24th, 2012 [January 24th, 2012]
- ACT Announces Aberdeen Royal Infirmary in Scotland as Additional Site for Phase 1/2 Clinical Trial Using hESC-Derived ... - January 30th, 2012 [January 30th, 2012]
- StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision - January 31st, 2012 [January 31st, 2012]
- $30 million donation from Boris family will help McMaster turn stem cell research into therapy - February 6th, 2012 [February 6th, 2012]
- Stem Cell Treatment For Blindness Shows Promise In Trials - February 7th, 2012 [February 7th, 2012]
- ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... - February 13th, 2012 [February 13th, 2012]